Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CNTA

Centessa Pharmaceuticals plc ADR

Last Close
May 14 • 01:44PM ET
9.09
Dollar change
+0.26
Percentage change
2.94 		%
Scroll to Statements
Index- P/E- EPS (ttm)-1.58 Insider Own29.57% Shs Outstand98.77M Perf Week-6.00%
Market Cap897.82M Forward P/E- EPS next Y-1.71 Insider Trans-0.19% Shs Float69.56M Perf Month-15.68%
Income-151.72M PEG- EPS next Q-0.42 Inst Own36.34% Short Float2.58% Perf Quarter-4.32%
Sales6.91M P/S129.93 EPS this Y-6.79% Inst Trans0.05% Short Ratio6.75 Perf Half Y46.38%
Book/sh2.39 P/B3.80 EPS next Y-1.69% ROA-37.59% Short Interest1.79M Perf Year95.48%
Cash/sh2.60 P/C3.50 EPS next 5Y- ROE-53.01% 52W Range3.96 - 12.45 Perf YTD14.20%
Dividend Est.- P/FCF- EPS past 5Y- ROI-47.29% 52W High-26.99% Beta1.42
Dividend TTM- Quick Ratio8.00 Sales past 5Y0.00% Gross Margin88.25% 52W Low129.55% ATR (14)0.64
Dividend Ex-Date- Current Ratio8.00 EPS Y/Y TTM31.55% Oper. Margin-2487.49% RSI (14)41.19 Volatility6.59% 6.34%
Employees76 Debt/Eq0.36 Sales Y/Y TTM- Profit Margin-2194.85% Recom1.40 Target Price13.60
Option/ShortYes / Yes LT Debt/Eq0.36 EPS Q/Q17.46% Payout- Rel Volume0.18 Prev Close8.83
Sales Surprise- EPS Surprise10.86% Sales Q/Q- EarningsMay 13 AMC Avg Volume265.69K Price9.09
SMA20-5.47% SMA50-13.31% SMA20012.37% Trades Volume31,353 Change2.94%
Date Action Analyst Rating Change Price Target Change
Nov-15-23Upgrade Jefferies Hold → Buy $4 → $11
Oct-26-23Upgrade Morgan Stanley Underweight → Equal-Weight $4 → $8
Jun-21-23Initiated Evercore ISI Outperform
Jun-12-23Initiated Guggenheim Buy $9
Mar-17-23Initiated SVB Securities Outperform $6
Aug-12-22Downgrade Morgan Stanley Overweight → Underweight $10 → $5
Jun-17-22Initiated BMO Capital Markets Outperform $19
Jun-03-22Downgrade Jefferies Buy → Hold $37 → $4
Feb-11-22Initiated Goldman Neutral $12
May-13-24 09:54PM
CNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q1 2024
(InvestorPlace)
04:10PM
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
(GlobeNewswire)
Apr-24-24 04:47AM
Centessa Pharmaceuticals Prices Equity Offering at $9.25 Per ADS
(MT Newswires)
Apr-23-24 09:36PM
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
(GlobeNewswire) -6.00%
06:00PM
Centessa Pharmaceuticals Eyes $100 Million in ADS Offering
(MT Newswires)
04:17PM Loading…
04:17PM
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
(GlobeNewswire)
Apr-22-24 07:00AM
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
(GlobeNewswire) -5.39%
Mar-28-24 11:53PM
CNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q4 2023
(InvestorPlace)
06:11PM
Centessa Pharmaceuticals PLC (CNTA) Earnings: A Detailed Look at Q4 and Full-Year 2023 Results
(GuruFocus.com)
04:28PM
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
(GlobeNewswire)
Mar-27-24 01:26AM
Centessa Pharmaceuticals PLC Chief People Officer Sells Company Shares
(GuruFocus.com)
Mar-18-24 08:01PM
7 Biotech Stocks Ready to Ride the Sectors Resurgence
(InvestorPlace)
Feb-22-24 08:00AM
Centessa Pharmaceuticals to Participate in TD Cowen's 44th Annual Health Care Conference
(GlobeNewswire)
Feb-09-24 07:00AM
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
(GlobeNewswire) +24.13%
Jan-22-24 08:00AM
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
(GlobeNewswire)
08:00AM Loading…
Dec-13-23 08:00AM
Centessa Pharmaceuticals to Present at the 42 Annual J.P. Morgan Healthcare Conference
(GlobeNewswire)
Dec-10-23 12:05PM
Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia
(GlobeNewswire)
Dec-05-23 09:55AM
Does Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) Have the Potential to Rally 40.85% as Wall Street Analysts Expect?
(Zacks)
Nov-27-23 04:15PM
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
(GlobeNewswire)
Nov-16-23 09:55AM
Wall Street Analysts Predict a 35.92% Upside in Centessa Pharmaceuticals PLC Sponsored ADR (CNTA): Here's What You Should Know
(Zacks)
Nov-14-23 07:28PM
Centessa Pharmaceuticals PLC Reports Q3 2023 Financial Results and Business Progress
(GuruFocus.com) +6.25%
Nov-13-23 04:05PM
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
(GlobeNewswire)
Nov-02-23 09:09AM
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting
(GlobeNewswire)
Oct-31-23 08:00AM
Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors
(GlobeNewswire)
Oct-30-23 08:00AM
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
(GlobeNewswire) +7.32%
Oct-25-23 08:00AM
Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750's Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders
(GlobeNewswire) -6.02%
Oct-03-23 08:00AM
Centessa Pharmaceuticals Announces Additions to Senior Leadership Team
(GlobeNewswire)
Sep-04-23 10:51AM
Centessa (CNTA) Surges 72% in the Past 3 Months: Here's Why
(Zacks)
Aug-31-23 08:00AM
Centessa Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
(GlobeNewswire) +6.35%
Aug-23-23 05:08PM
Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress
(GlobeNewswire)
07:00AM Loading…
Aug-14-23 07:00AM
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023
(GlobeNewswire)
Jul-10-23 08:00AM
Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors
(GlobeNewswire) +5.04%
May-24-23 08:00AM
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
(GlobeNewswire)
May-22-23 07:00AM
Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B
(GlobeNewswire)
May-12-23 07:00AM
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023
(GlobeNewswire)
Apr-27-23 12:07PM
Centessa Pharmaceuticals plc (NASDAQ:CNTA) most popular amongst private equity firms who own 42% of the shares, institutions hold 22%
(Simply Wall St.) -5.71%
Mar-30-23 07:00AM
Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022
(GlobeNewswire)
Mar-27-23 08:00AM
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Mar-23-23 04:30PM
Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director
(PR Newswire)
08:32AM
Should You Buy Centessa Pharmaceuticals (CNTA) Ahead of Earnings?
(Zacks)
Mar-01-23 08:00AM
Centessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines
(GlobeNewswire)
Feb-06-23 08:00AM
Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
(GlobeNewswire)
Feb-02-23 08:00AM
Centessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma Conference
(GlobeNewswire)
Jan-26-23 09:08AM
Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors
(GlobeNewswire)
Dec-10-22 03:30PM
Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia
(GlobeNewswire)
Nov-30-22 08:00AM
Centessa Pharmaceuticals Announces New Chief People Officer Karen Anderson
(GlobeNewswire)
Nov-18-22 10:29AM
While institutions own 29% of Centessa Pharmaceuticals plc (NASDAQ:CNTA), private equity firms are its largest shareholders with 42% ownership
(Simply Wall St.)
Nov-10-22 07:00AM
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2022
(GlobeNewswire)
Nov-03-22 09:04AM
Centessa Pharmaceuticals to Present Additional 18-Months of Continued Treatment Data with SerpinPC from Open-Label Extension of Phase 2a Study at 64th ASH Annual Meeting
(GlobeNewswire)
Oct-31-22 08:00AM
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Sep-20-22 08:33AM
Centessa Pharmaceuticals Announces Poster Presentation Featuring Novel Orexin Receptor 2 (OX2R) Agonist Discovery Pipeline at the 26th Conference of the European Sleep Research Society (Sleep Europe 2022)
(GlobeNewswire)
Sep-14-22 09:00AM
Centessa Pharmaceuticals Announces Orphan Drug Designation Granted to SerpinPC for the Treatment of Hemophilia B
(GlobeNewswire) +8.92%
Sep-12-22 07:00AM
Centessa Pharmaceuticals Announces Non-Human Primate Pharmacokinetic and Safety Data for LB101 (PD-L1xCD47) Demonstrating Potential for Enhanced Therapeutic Index
(GlobeNewswire)
Aug-29-22 08:00AM
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Aug-10-22 08:37AM
Centessa Culls Early-Stage Asset For Inherited Disorder
(Benzinga) -5.19%
06:30AM
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2022; Provides Program Update for ZF874
(GlobeNewswire)
Jul-29-22 05:00AM
Why are Massachusetts CEOs paid so much money? Here's a primer
(American City Business Journals)
Jul-25-22 08:00AM
Centessa Pharmaceuticals Announces Addition of Harris L. Rotman, PhD, as Senior Vice President of Regulatory Affairs
(GlobeNewswire)
Jul-01-22 08:40AM
Centessa Pharmaceuticals Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors
(GlobeNewswire) +6.16%
Jun-23-22 09:55AM
Wall Street Analysts Predict a 128% Upside in Centessa Pharmaceuticals PLC Sponsored ADR (CNTA): Here's What You Should Know
(Zacks)
Jun-17-22 02:35PM
BMO Capital Sees Almost 300% Upside On Centessa Stock
(Benzinga) +19.08%
Jun-11-22 10:06AM
What Kind Of Investors Own Most Of Centessa Pharmaceuticals plc (NASDAQ:CNTA)?
(Simply Wall St.)
Jun-06-22 08:00AM
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Jun-05-22 07:00AM
Centessa Pharmaceuticals Announces Poster Presentation of First Preclinical Data for LockBody® Program at 2022 ASCO Annual Meeting
(GlobeNewswire)
Jun-03-22 08:29AM
Record-Setting Biotech Plunges 25% After Axing Lead Program
(TheStreet.com)
Jun-02-22 06:29AM
Centessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
(GlobeNewswire) -27.78%
May-16-22 07:00AM
Centessa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Updates
(GlobeNewswire)
Mar-30-22 04:01PM
Centessa Pharmaceuticals Reports Fourth Quarter and 2021 Financial Results and Provides Business Update
(GlobeNewswire)
Mar-23-22 04:30PM
Centessa Pharmaceuticals to Present at the Guggenheim Genomic Medicines & Rare Disease Day
(GlobeNewswire)
Mar-07-22 07:30AM
Centessa Pharmaceuticals Expands Management Team and Adds to Extensive Development Expertise
(GlobeNewswire)
Feb-24-22 07:30AM
Centessa Pharmaceuticals Doses First Subject in Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease
(GlobeNewswire)
Feb-17-22 02:38AM
Top 10 Stock Picks of Srini Akkaraju and Michael Dybbs Samsara BioCapital
(Insider Monkey)
Jan-01-22 07:33AM
Do Institutions Own Centessa Pharmaceuticals Limited (NASDAQ:CNTA) Shares?
(Simply Wall St.)
Dec-21-21 06:38PM
Boxer Capital, Llc Buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, ...
(GuruFocus.com) +10.06%
Dec-14-21 07:30AM
Centessa Pharmaceuticals Initiates Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease, Reports Initial Positive Safety Data from ALERT Study, and Announces Notice of Allowance for Key Lixivaptan U.S. Patent Application
(GlobeNewswire) -9.39%
Dec-13-21 04:15PM
Centessa Pharmaceuticals Announces Addition to NASDAQ Biotechnology Index
(GlobeNewswire)
Dec-06-21 05:00PM
2 Big Stock Bets That Are Insiders Are Buying Now
(InvestorPlace) -5.58%
Nov-24-21 06:59AM
Centessa Pharmaceuticals (CNTA) Sees Hammer Chart Pattern: Time to Buy?
(Zacks)
Nov-15-21 07:00AM
Centessa Pharmaceuticals Announces Third Quarter 2021 Financial Results and Business Updates
(GlobeNewswire)
Nov-10-21 04:45PM
Centessa Pharmaceuticals to Present at Upcoming Conferences in 2021
(GlobeNewswire)
Nov-01-21 07:29PM
Why Did Centessa's Shares Plunge 10% Today?
(Benzinga) -18.55%
10:35AM
Mid-Morning Market Update: Markets Mixed; PG&E Earnings Miss views
(Benzinga)
07:30AM
Centessa Pharmaceuticals Demonstrates Proof-of-Mechanism from First Three PiMZ Subjects Dosed in Part B of Phase 1 Study Evaluating ZF874
(GlobeNewswire)
Oct-18-21 08:00AM
Centessa Pharmaceuticals Subsidiary, Orexia Therapeutics, and Schrödinger Announce Collaboration to Discover Novel Orexin Receptor Agonists
(Business Wire)
Oct-05-21 08:00AM
Centessa Pharmaceuticals Appoints David Grainger, PhD, a Leading Biotech Entrepreneur, as Chief Innovation Officer
(GlobeNewswire)
Oct-04-21 08:00AM
Centessa Pharmaceuticals Announces $300 Million Financing Agreement with Oberland Capital
(GlobeNewswire)
Sep-29-21 08:47AM
15 Biotech Stocks to Buy Now According to Srini Akkaraju and Michael Dybbs Samsara BioCapital
(Insider Monkey)
Sep-09-21 12:01PM
35 Stocks Moving In Thursday's Mid-Day Session
(Benzinga) +5.75%
07:30AM
Centessa Pharmaceuticals Announces Positive Topline Data from Proof-of-Concept Study of SerpinPC in Severe Hemophilia A and B Patients Not on Prophylaxis
(GlobeNewswire)
Sep-01-21 04:15PM
Centessa Pharmaceuticals to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference
(GlobeNewswire)
Aug-16-21 07:00AM
Centessa Pharmaceuticals Announces Second Quarter 2021 Financial Results and Business Updates
(GlobeNewswire)
Jul-14-21 08:06AM
Goldman Sachs Sees These 3 Stocks Skyrocketing Over 60%
(TipRanks)
Jun-07-21 04:15PM
Centessa Pharmaceuticals to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
(GlobeNewswire)
04:00AM
Citi Appointed as Depositary Bank for Centessa Pharmaceuticals plcs ADR Programme
(Business Wire)
Jun-04-21 04:15PM
Centessa Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional ADSs
(GlobeNewswire)
May-27-21 10:49PM
Centessa Announces Pricing of Initial Public Offering
(Business Wire)
Centessa Pharmaceuticals Plc operates as clinical-stage pharmaceutical company, which engages in discovering and developing medicines that delivers transformational to patients. Its portfolio include preclinical to phase three uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. The company was founded on October 26, 2020 and is headquartered in Altrincham, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Anderson Karen M.Chief People OfficerMar 25 '24Option Exercise3.9445,000177,252122,685Mar 26 04:16 PM
Anderson Karen M.Chief People OfficerMar 25 '24Sale11.8851,160607,96071,525Mar 26 04:16 PM
Rotman HarrisSVP Regulatory AffairsFeb 01 '24Sale8.104,26734,57462,625Feb 02 05:03 PM
Rotman HarrisSVP Regulatory AffairsSep 20 '23Option Exercise4.3737,484163,68870,984Sep 22 04:47 PM
Rotman HarrisSVP Regulatory AffairsSep 20 '23Sale6.2937,484235,68833,500Sep 22 04:47 PM
YVER ANTOINEEVP & Chairman of DevelopmentJun 01 '23Sale4.456,50028,949783,066Jun 02 05:01 PM
Bush Tia LChief Quality OfficerMay 24 '23Sale4.488,00035,8650May 26 05:01 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.